Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,580,306

« Back to Dashboard

Which drugs does patent 8,580,306 protect, and when does it expire?


Patent 8,580,306 protects SEEBRI and UTIBRON and is included in two NDAs.

This patent has one hundred and ninety patent family members in thirty-three countries.

Summary for Patent: 8,580,306

Title:Particles for use in a pharmaceutical composition
Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 .mu.m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolization of a dry, powder in a dry powder inhaler.
Inventor(s): Staniforth; John Nicholas (Bath, GB), Morton; David Alexander Vodden (Bath, GB)
Assignee: Vectura Limited (Chippenham, GB)
Application Number:10/433,135
Patent Claim Types:
see list of patent claims
Use; Composition; Process; Formulation; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes8,580,306► SubscribeY
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes8,580,306► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,580,306

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0029261.5Nov 30, 2000
United Kingdom0030946.8Dec 19, 2000
United Kingdom0124009.2Oct 5, 2001
PCT Information
PCT FiledNovember 30, 2001PCT Application Number:PCT/GB01/05305
PCT Publication Date:June 06, 2002PCT Publication Number: WO02/43700

Non-Orange Book Patents for Patent: 8,580,306

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,744,855Method of making particles for use in a pharmaceutical composition► Subscribe
7,229,607Treatment of respiratory disease► Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
9,351,928Method of making particles for use in a pharmaceutical composition► Subscribe
8,956,661Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,580,306

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway20024708► Subscribe
Brazil0109875► Subscribe
Brazil0110139► Subscribe
Brazil0110141► Subscribe
Brazil0110301► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot